Patrick Sartore Sells 64,579 Shares of ProMetic Life Sciences Inc. (PLI) Stock
ProMetic Life Sciences Inc. (TSE:PLI) insider Patrick Sartore sold 64,579 shares of the firm’s stock in a transaction that occurred on Thursday, August 24th. The stock was sold at an average price of C$1.15, for a total value of C$74,265.85.
Patrick Sartore also recently made the following trade(s):
- On Friday, August 18th, Patrick Sartore acquired 9,250 shares of ProMetic Life Sciences stock. The stock was purchased at an average price of C$1.21 per share, with a total value of C$11,192.50.
Shares of ProMetic Life Sciences Inc. (PLI) traded up 25.00% during mid-day trading on Tuesday, hitting $1.50. The company’s stock had a trading volume of 5,786,854 shares. ProMetic Life Sciences Inc. has a 1-year low of $1.12 and a 1-year high of $3.24. The company’s market cap is $1.06 billion. The company has a 50-day moving average of $1.48 and a 200 day moving average of $1.96.
TRADEMARK VIOLATION NOTICE: “Patrick Sartore Sells 64,579 Shares of ProMetic Life Sciences Inc. (PLI) Stock” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://www.watchlistnews.com/patrick-sartore-sells-64579-shares-of-prometic-life-sciences-inc-pli-stock/1530400.html.
PLI has been the subject of a number of research reports. Scotiabank reduced their price objective on ProMetic Life Sciences from C$4.75 to C$4.00 and set an “outperform” rating for the company in a research report on Friday, July 7th. Canaccord Genuity reduced their price objective on ProMetic Life Sciences from C$4.75 to C$4.50 and set a “buy” rating for the company in a research report on Monday, June 19th. Royal Bank Of Canada reiterated an “outperform” rating on shares of ProMetic Life Sciences in a research report on Wednesday, May 24th. Finally, TD Securities reduced their price objective on ProMetic Life Sciences from C$4.50 to C$3.50 and set a “speculative buy” rating for the company in a research report on Wednesday, August 16th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. ProMetic Life Sciences presently has an average rating of “Buy” and a consensus target price of C$3.88.
About ProMetic Life Sciences
Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.
Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.